|

BMS-986504 Clinical Trials

9 actively recruiting trials across 6 locations

▲ +1 trial since August 2026

Also known as: MRTX1719, Navlimetostat

Pipeline

Early 1: 1Phase 1: 3Phase 2: 3Phase 1/2: 1Phase 2/3: 1

Top Sponsors

  • Bristol-Myers Squibb5
  • Nader Sanai1
  • Memorial Sloan Kettering Cancer Center1
  • M.D. Anderson Cancer Center1
  • Ankit Mangla, MD1

Indications

  • Cancer9
  • Lung Cancer3
  • Gastroesophageal Carcinoma1
  • Diffuse Pleural Mesothelioma1
  • MTAP-deleted Pancreatic Cancer1

Other2 trials

A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors
Phase 1
A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion
Phase 1

Anchorage, Alaska2 trials

A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

Alaska Oncology and Hematology

Phase 2
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Local Institution - 0119

Phase 2/3

Phoenix, Arizona1 trial

Clinical Trial of BMS-986504 in Recurrent GBM Patients

St. Joseph's Hospital and Medical Center

Early 1

San Francisco, California1 trial

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Local Institution - 0096

Phase 2

Basking Ridge, New Jersey1 trial

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Phase 1

Cleveland, Ohio1 trial

Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor

University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

Phase 1/2

Houston, Texas1 trial

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

MD Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.